Modern oncology is undergoing a paradigm shift with the emergence of the Combined Risk Score cancer assessment tool. While Polygenic Risk Scores (PRS) have traditionally measured inherited susceptibility, they often ignore the critical impact of environmental factors. Researchers now advocate for an integrated approach that combines genetic data with the human exposome. This comprehensive model accounts for cumulative, time-varying exposures that significantly influence an individual’s cancer trajectory.

The Evolution of the Combined Risk Score Cancer Model

The human exposome encompasses every non-genetic exposure an individual encounters throughout their life course. Consequently, treating environmental inputs as isolated covariates is no longer sufficient for accurate risk modeling. By leveraging artificial intelligence, clinicians can now synthesize massive datasets from genome-wide association studies and environmental cohorts. This synergy enables the creation of a more robust Combined Risk Score cancer profile. Furthermore, these models consistently demonstrate a monotonic increase in relative risk across higher score percentiles. However, despite these advancements, the transition from research models to clinical decision systems requires caution.

Addressing the Prediction Gap in Precision Oncology

A significant challenge in current risk modeling is the distinction between etiologic association and predictive performance. Many studies show that while CRS and PRS can identify relative risks, their absolute gains in metrics like the area under the curve (AUC) remain modest. Moreover, calibration performance varies across different populations. This suggests that the Combined Risk Score cancer is currently most effective for population-level stratification rather than individual diagnosis. Clinicians should prioritize these tools for targeted screening and prevention trials. Additionally, addressing population stratification and ensuring multi-ancestry evaluation is essential for achieving health equity.

Future Directions for Clinical Translation

To advance these exploratory models into clinical tools, researchers must focus on external validation and methodological transparency. The most immediate value of CRS lies in risk-enriched research designs and prioritized screening strategies. Furthermore, governance and ethical considerations must guide the implementation of AI-driven risk assessments. By refining these data requirements, the medical community can move closer to robust, population-appropriate cancer prevention tools.

Frequently Asked Questions

How does the Combined Risk Score differ from a Polygenic Risk Score?

While a Polygenic Risk Score (PRS) only measures inherited genetic susceptibility, a Combined Risk Score (CRS) integrates both genomic data and the human exposome. This includes environmental, lifestyle, and cumulative exposures across an individual's life.

Can the Combined Risk Score be used as a standalone diagnostic tool?

No, current evidence suggests that these scores are best used for risk stratification, prioritization, and population-level screening rather than as standalone clinical decision-making systems.

Why is calibration important in cancer risk models?

Calibration ensures that the predicted risk matches the observed risk in specific populations. Without proper calibration, models may over- or underestimate risk, leading to inappropriate clinical interventions.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare providers with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sarigiannis D et al. AI-driven integration of genomic and exposome data for cancer risk: the combined risk score (CRS). Hum Genomics. 2026 May 04. doi: 10.1186/s40246-026-00969-0. PMID: 42083001.

Conran C et al. Assessing the clinical utility of genetic risk scores for targeted cancer screening. J Transl Med. 2021;19(1):37. doi: 10.1186/s12967-020-02699-w.

Kramer I et al. Polygenic risk scores in clinical practice? Still making the case. CDC Office of Genomics and Precision Public Health. 2022 Jul 05.